It is a top Greek enterprise in investment in research, ranked 46th on the basis of investment in research among 4577 pharmaceutical companies operating in the EU; it is among the 50 largest and most profitable companies in Greece, and it is ranked 435th in the top 1000 largest EU based ‘Research & Development’ companies.
Now, the Greek pharmaceutical company and one of the largest Greek exporting companies, Pharmathen has expanded to Australia.
Founded in 1969 in Athens, as a private pharmaceutical company by the Katsos family, Pharmathen commenced its manufacturing activities in 1972.
It was in 1993 that the then small and insignificant pharmaceutical family business entered the worldwide market, as the leadership was passed to Vassilios Katsos and Nelly Katsou, and its first export activities commenced in 1995.
Focused on the development and marketing of pharmaceuticals, with a strong position in generics, Pharmathen is a purely Greek pharmaceutical company operating worldwide. Since 2012, Pharmathen has expanded in the Asia-Pacific region, including Australia and New Zealand, where its extensive portfolio of products – original and generic drugs as well as pharmaceutical and parapharmaceutical products – are now available.
Today, almost 50 years after it was founded, Pharmathen has three research laboratories and two industrial plants. It’s a model-company of Greek entrepreneurship, as it is the largest investor in research & development in Greece with 20 million euros per year, and a turnover of 162 million euros for 2012. The company’s export activity constitutes around 1 per cent of the country’s total exports.
Its human resources include more than 800 people who work in the sectors of research & development, production and distribution of drugs in more than 85 countries worldwide.
The company’s most recently opened offices include Jordan and Australia and permanent representation in South America, whilst its products are approved in all EU countries.